vs

Side-by-side financial comparison of G III APPAREL GROUP LTD (GIII) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

G III APPAREL GROUP LTD is the larger business by last-quarter revenue ($988.6M vs $961.0M, roughly 1.0× DENTSPLY SIRONA Inc.). G III APPAREL GROUP LTD runs the higher net margin — 8.2% vs -15.2%, a 23.3% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -9.0%). DENTSPLY SIRONA Inc. produced more free cash flow last quarter ($60.0M vs $-106.4M). Over the past eight quarters, G III APPAREL GROUP LTD's revenue compounded faster (13.7% CAGR vs 0.4%).

G III Apparel Group is a global fashion company that designs, sources, manufactures, markets and distributes apparel, footwear, and accessories under a range of owned and licensed well-known brands. It serves department stores, specialty retailers, and e-commerce platforms across North America, Europe, and other key global markets, catering to casual, sportswear, and premium fashion consumer segments.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

GIII vs XRAY — Head-to-Head

Bigger by revenue
GIII
GIII
1.0× larger
GIII
$988.6M
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+15.2% gap
XRAY
6.2%
-9.0%
GIII
Higher net margin
GIII
GIII
23.3% more per $
GIII
8.2%
-15.2%
XRAY
More free cash flow
XRAY
XRAY
$166.4M more FCF
XRAY
$60.0M
$-106.4M
GIII
Faster 2-yr revenue CAGR
GIII
GIII
Annualised
GIII
13.7%
0.4%
XRAY

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
GIII
GIII
XRAY
XRAY
Revenue
$988.6M
$961.0M
Net Profit
$80.6M
$-146.0M
Gross Margin
38.6%
46.1%
Operating Margin
11.4%
-14.5%
Net Margin
8.2%
-15.2%
Revenue YoY
-9.0%
6.2%
Net Profit YoY
-29.8%
66.0%
EPS (diluted)
$1.84
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GIII
GIII
XRAY
XRAY
Q4 25
$988.6M
$961.0M
Q3 25
$613.3M
$904.0M
Q2 25
$583.6M
$936.0M
Q1 25
$839.5M
$879.0M
Q4 24
$1.1B
$905.0M
Q3 24
$644.8M
$951.0M
Q2 24
$609.7M
$984.0M
Q1 24
$764.8M
$953.0M
Net Profit
GIII
GIII
XRAY
XRAY
Q4 25
$80.6M
$-146.0M
Q3 25
$10.9M
$-427.0M
Q2 25
$7.8M
$-45.0M
Q1 25
$48.8M
$20.0M
Q4 24
$114.8M
$-430.0M
Q3 24
$24.2M
$-494.0M
Q2 24
$5.8M
$-4.0M
Q1 24
$28.9M
$18.0M
Gross Margin
GIII
GIII
XRAY
XRAY
Q4 25
38.6%
46.1%
Q3 25
40.8%
48.8%
Q2 25
42.2%
52.4%
Q1 25
39.5%
53.0%
Q4 24
39.8%
49.3%
Q3 24
42.8%
52.1%
Q2 24
42.5%
51.9%
Q1 24
36.9%
53.1%
Operating Margin
GIII
GIII
XRAY
XRAY
Q4 25
11.4%
-14.5%
Q3 25
2.7%
-24.1%
Q2 25
1.5%
-13.7%
Q1 25
8.5%
7.2%
Q4 24
15.3%
-56.2%
Q3 24
6.4%
-48.6%
Q2 24
2.2%
5.1%
Q1 24
6.1%
4.4%
Net Margin
GIII
GIII
XRAY
XRAY
Q4 25
8.2%
-15.2%
Q3 25
1.8%
-47.2%
Q2 25
1.3%
-4.8%
Q1 25
5.8%
2.3%
Q4 24
10.6%
-47.5%
Q3 24
3.8%
-51.9%
Q2 24
1.0%
-0.4%
Q1 24
3.8%
1.9%
EPS (diluted)
GIII
GIII
XRAY
XRAY
Q4 25
$1.84
$-0.74
Q3 25
$0.25
$-2.14
Q2 25
$0.17
$-0.22
Q1 25
$1.00
$0.10
Q4 24
$2.55
$-2.09
Q3 24
$0.53
$-2.46
Q2 24
$0.12
$-0.02
Q1 24
$0.59
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GIII
GIII
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$184.1M
$326.0M
Total DebtLower is stronger
$6.5M
$2.3B
Stockholders' EquityBook value
$1.8B
$1.3B
Total Assets
$2.8B
$5.4B
Debt / EquityLower = less leverage
0.00×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GIII
GIII
XRAY
XRAY
Q4 25
$184.1M
$326.0M
Q3 25
$301.8M
$363.0M
Q2 25
$257.8M
$359.0M
Q1 25
$181.4M
$398.0M
Q4 24
$104.7M
$272.0M
Q3 24
$414.8M
$296.0M
Q2 24
$508.4M
$279.0M
Q1 24
$507.8M
$291.0M
Total Debt
GIII
GIII
XRAY
XRAY
Q4 25
$6.5M
$2.3B
Q3 25
$6.9M
Q2 25
$6.8M
Q1 25
$3.0M
Q4 24
$213.9M
$1.7B
Q3 24
$402.5M
Q2 24
$402.7M
Q1 24
$402.8M
Stockholders' Equity
GIII
GIII
XRAY
XRAY
Q4 25
$1.8B
$1.3B
Q3 25
$1.7B
$1.5B
Q2 25
$1.7B
$2.0B
Q1 25
$1.7B
$2.0B
Q4 24
$1.6B
$1.9B
Q3 24
$1.5B
$2.5B
Q2 24
$1.5B
$3.1B
Q1 24
$1.6B
$3.3B
Total Assets
GIII
GIII
XRAY
XRAY
Q4 25
$2.8B
$5.4B
Q3 25
$2.7B
$5.7B
Q2 25
$2.4B
$6.1B
Q1 25
$2.5B
$6.0B
Q4 24
$2.8B
$5.8B
Q3 24
$2.7B
$6.6B
Q2 24
$2.6B
$6.9B
Q1 24
$2.7B
$7.1B
Debt / Equity
GIII
GIII
XRAY
XRAY
Q4 25
0.00×
1.70×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.13×
0.90×
Q3 24
0.27×
Q2 24
0.26×
Q1 24
0.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GIII
GIII
XRAY
XRAY
Operating Cash FlowLast quarter
$-97.3M
$101.0M
Free Cash FlowOCF − Capex
$-106.4M
$60.0M
FCF MarginFCF / Revenue
-10.8%
6.2%
Capex IntensityCapex / Revenue
0.9%
4.3%
Cash ConversionOCF / Net Profit
-1.21×
TTM Free Cash FlowTrailing 4 quarters
$367.7M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GIII
GIII
XRAY
XRAY
Q4 25
$-97.3M
$101.0M
Q3 25
$75.1M
$79.0M
Q2 25
$93.8M
$48.0M
Q1 25
$333.4M
$7.0M
Q4 24
$-111.8M
$87.0M
Q3 24
$49.3M
$141.0M
Q2 24
$45.5M
$208.0M
Q1 24
$361.3M
$25.0M
Free Cash Flow
GIII
GIII
XRAY
XRAY
Q4 25
$-106.4M
$60.0M
Q3 25
$64.7M
$40.0M
Q2 25
$85.7M
$16.0M
Q1 25
$323.7M
$-12.0M
Q4 24
$-120.3M
$36.0M
Q3 24
$38.8M
$98.0M
Q2 24
$32.8M
$156.0M
Q1 24
$352.3M
$-9.0M
FCF Margin
GIII
GIII
XRAY
XRAY
Q4 25
-10.8%
6.2%
Q3 25
10.6%
4.4%
Q2 25
14.7%
1.7%
Q1 25
38.6%
-1.4%
Q4 24
-11.1%
4.0%
Q3 24
6.0%
10.3%
Q2 24
5.4%
15.9%
Q1 24
46.1%
-0.9%
Capex Intensity
GIII
GIII
XRAY
XRAY
Q4 25
0.9%
4.3%
Q3 25
1.7%
4.3%
Q2 25
1.4%
3.4%
Q1 25
1.2%
2.2%
Q4 24
0.8%
5.6%
Q3 24
1.6%
4.5%
Q2 24
2.1%
5.3%
Q1 24
1.2%
3.6%
Cash Conversion
GIII
GIII
XRAY
XRAY
Q4 25
-1.21×
Q3 25
6.86×
Q2 25
12.09×
Q1 25
6.83×
0.35×
Q4 24
-0.97×
Q3 24
2.04×
Q2 24
7.84×
Q1 24
12.52×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GIII
GIII

Proprietary Brands$498.1M50%
Licensed Brands$479.2M48%
Retail Segment$45.7M5%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons